RecruitingPhase 3NCT06100744
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Sponsor: AbbVie
New York, NY · Valhalla, NY · +10 more sites